SG11201811160XA - Treatment for myopia - Google Patents
Treatment for myopiaInfo
- Publication number
- SG11201811160XA SG11201811160XA SG11201811160XA SG11201811160XA SG11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA SG 11201811160X A SG11201811160X A SG 11201811160XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- myopia
- pct
- new south
- south wales
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIP0 I PCT Iiiimmomiolollmolomm VIII iflo Hs (10) International Publication Number WO 2017/219080 Al 1-1 GC 1-1 N 1-1 O O (51) International Patent Classification: A61K 31/198 (2006.01) A61P 27/02 (2006.01) A61K 31/04 (2006.01) (21) International Application Number: PCT/AU2017/050627 (22) International Filing Date: 21 June 2017 (21.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016902429 21 June 2016 (21.06.2016) AU (71) Applicant: THE UNIVERSITY OF NEWCASTLE [AU/AU]; 130 University Drive, Callaghan, New South Wales 2308 (AU). (72) Inventor: MCFADDEN, Sally Anne; 56 Dawson Street, Cooks Hill, New South Wales 2300 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; 255 Elizabeth Street, Sydney, New South Wales 2000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) = (54) Title: TREATMENT FOR MYOPIA FIGURE 1 A B Diffe re nce in Refrac t ive Erro r ( D) Diffe re nce in Ocu la Le r ng t h (p. m) 150 100 50 0 -50 - 100 - 150 -6D Plano Rec -6D Plano Rec (57) : Provided herein are methods for treating or preventing myopia, or for inhibiting the development of myopia, comprising administering to a subject in need thereof an effective amount of an agent capable of increasing nitric oxide levels in one or more ocular cells or an agent capable of promoting or increasing the expression and/or activity of nNOS in one or more ocular cells. Also provided are methods for inducing or promoting nNOS expression and/or activity in one or more ocular cells, comprising exposing said cells to an effective amount of L-arginine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016902429A AU2016902429A0 (en) | 2016-06-21 | Treatment for myopia | |
PCT/AU2017/050627 WO2017219080A1 (en) | 2016-06-21 | 2017-06-21 | Treatment for myopia |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811160XA true SG11201811160XA (en) | 2019-01-30 |
Family
ID=60783610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811160XA SG11201811160XA (en) | 2016-06-21 | 2017-06-21 | Treatment for myopia |
Country Status (4)
Country | Link |
---|---|
US (1) | US10945980B2 (en) |
CN (1) | CN109640973A (en) |
SG (1) | SG11201811160XA (en) |
WO (1) | WO2017219080A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3763280A1 (en) * | 2019-07-11 | 2021-01-13 | Carl Zeiss Vision International GmbH | Determination of a change in the refraction error of an eye |
CN110934865A (en) * | 2019-12-06 | 2020-03-31 | 牡丹江医学院 | Pharmaceutical composition for preventing and treating hemodialysis hypotension and application thereof |
EP4157453A1 (en) * | 2020-06-02 | 2023-04-05 | The Trustees of Columbia University in the City of New York | Methods and compositions for preventing and treating myopia with levocabastine, a selective histamine h1-receptor antagonist, and derivatives thereof |
JP2023529943A (en) * | 2020-06-11 | 2023-07-12 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Methods and compositions for preventing and treating myopia using S-methyl-L-thiocitrulline, a selective neuronal nitric oxide synthase (NNOS) inhibitor, and derivatives thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3490300A (en) * | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
AU779991B2 (en) * | 1999-08-10 | 2005-02-24 | Board Of Regents, The University Of Texas System | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
CN1390124A (en) * | 2000-09-20 | 2003-01-08 | 永光制药有限公司 | Medicine for preventing or treating myopia |
RU2635185C2 (en) * | 2013-12-17 | 2017-11-09 | Иван Дмитриевич Захаров | Pharmaceutical preparation for prevention and treatment of progressive myopia |
-
2017
- 2017-06-21 CN CN201780051455.8A patent/CN109640973A/en active Pending
- 2017-06-21 US US16/310,587 patent/US10945980B2/en active Active
- 2017-06-21 WO PCT/AU2017/050627 patent/WO2017219080A1/en active Application Filing
- 2017-06-21 SG SG11201811160XA patent/SG11201811160XA/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20190142778A1 (en) | 2019-05-16 |
US10945980B2 (en) | 2021-03-16 |
CN109640973A (en) | 2019-04-16 |
WO2017219080A1 (en) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
SG11201810003UA (en) | Using programmable dna binding proteins to enhance targeted genome modification | |
SG11201908857QA (en) | Methods for the treatment of inflammation and inflammatory conditions | |
SG11201811160XA (en) | Treatment for myopia | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201810443SA (en) | Invasive medical devices including magnetic region and systems and methods | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201809341PA (en) | Mobile robot | |
SG11201805381TA (en) | Electroporation device with detachable needle array with lock-out system | |
SG11201809605PA (en) | Compositions for and method of treating acid-base disorders | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201900057WA (en) | Biomatrix scaffolds for use in diagnosing and modeling cancer | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201805184TA (en) | Combination therapy | |
SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |